The DEA extended telemedicine prescribing flexibilities for controlled substances through the end of 2026, drawing praise from telehealth advocates who are urging a permanent solution.
A group of healthcare organizations sent a letter to Congressional leaders urging them to permanently extend Medicare telehealth flexibilities introduced during the Covid-19 pandemic.
CEO and neuroscientist Dr. Iftach Dolev on how the new device can bring a powerful tool to psychiatrists and neurologists alike.
The DEA recently released three rules regarding the remote prescribing of controlled substances. However, many telehealth advocates argue that two of these rules hinder access to care.